. 2023 Oct 15;13(5):291–299.

Table 2.

Summary of the included studies

Study ID	Country	Study Design	Number of participants	Follow up duration	Conclusion
Paitazoglou et al.	4 European centers	Retrospective registry	W-FLX: 164	3 months	Improved sealing rate with similar safety profile.
Paitazoglou et al.	4 European centers	Retrospective registry	W 2.5: 1025	3 months	Improved sealing rate with similar safety profile.
Vizzari et al.	Italy	Prospective nonrandomized double-center registry	W-FLX: 200	272 ± 172.76 days	High success rates with W-FLX with good sealing and low rates of complications including DRT, distal embolization.
Vizzari et al.	Italy	Prospective nonrandomized double-center registry	W 2.5: 100	272 ± 172.76 days
Price et al.	USA	NCDR LAAO	W-FLX: 27,013	In-hospital and peri-procedural	W-FLX had Lower rates of MAE, mortality, embolization, bleeding and cardiac arrest.
Price et al.	USA	NCDR LAAO	W 2.5: 27,013	In-hospital and peri-procedural
Fukuda et al.	Japan	Retrospective single-center study	W-FLX: 44	45 days	W-FLX was as safe and effective as conventional W 2.5 during the short-term period.
Fukuda et al.	Japan	Retrospective single-center study	W 2.5: 49	45 days
Galea et al.	Switzerland	Prospective cohort	W-FLX: 73	6 months	W-FLX as compared to W 2.5, was associated with similar procedure-related complications and 6-month NACE, but with improved LAA neck coverage, and lower IDL and DRT.
Galea et al.	Switzerland	Prospective cohort	W 2.5: 71	6 months

W-FLX: Watchman FLX; W 2.5: Watchman 2.5; DRT: Device-Related Thrombus; NCDR LAAO Registry: The National Cardiovascular Data Registry Left Atrial Appendage Occlusion; MAE: Major Adverse Events; NACE: Net Adverse Cardiovascular Events; LAA: Left Atrial Appendage; IDL: Intra-Device Leak.